Targeted NGS, endpoint RT-PCR and RT-qPCR platforms give researchers much greater power when profiling tumor samples. However, they present challenges surrounding sample variability, RNA extraction procedures, RNA quantification, platform bias, and potential failure to detect biomarkers. To meet this need, Horizon has developed a targeted EML4-ALK, CCDC6-RET and SLC34A2-ROS1 verified cell line multiplex in an FFPE format. This renewable and highly-characterised biologically-relevant reference materials contain cell lines that were either engineered or clonally derived from a fusion background. The utilisation of clonal cell populations derived from single cell dilution and controlled manufacturing environment ensure reproducible amplifiable levels of EML4-ALKv1, CCDC6-RET and SLC34A2-ROS1 allowing for a consistent external quality control.
• Assess the performance of your RNA-seq, endpoint RT-PCR or RT-qPCR aimed at detecting EML4-ALK, CCDC6-RET and SLC34A2-ROS1 fusions
• Ensure confidence in your clinical workflow, from RNA extraction to analysis
• Assess analytical variability and reproducibility between platforms, laboratories, operators and assays